Immunotherapy and targeted drug before surgery for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests two drugs—camrelizumab (an immunotherapy) and dalpiciclib (a targeted therapy)—given before surgery for head and neck squamous cell carcinoma that can be removed. The goal is to see if this combination helps shrink the tumor and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of head and neck cancer (not nasopharyngeal) that is newly diagnosed and has not spread to other parts of the body.
- A head and neck surgeon must have said the tumor can be removed with surgery, and you must be willing to have that surgery.
- You must be in generally good health (able to do daily activities without help, and have normal organ function).
- You must not have had other cancers in the past 5 years, severe autoimmune diseases, serious heart or lung problems, active infections like hepatitis B or C, or a history of drug allergies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests whether combining an immunotherapy drug (camrelizumab) with another targeted therapy or chemotherapy given before and after surgery can improve outcomes for people with locally advanced head and neck cancer. It aims to see if this approach is more effective than standard treatments.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.
This trial tests a combination of two drugs (Adebrelimab, an immunotherapy that helps your immune system attack cancer cells, and Dalpiciclib, a targeted therapy that stops cancer cells from dividing) given before surgery for a type of head and neck cancer. It is looking at whether this treatment can improve outcomes for people with HPV-negative, locally advanced head and neck squamous cell carcinoma that can be surgically removed.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
This trial compares two immunotherapy drugs (ivonescimab vs. pembrolizumab) given before and after surgery for head and neck cancer that can be surgically removed. The goal is to see which drug works better to shrink the tumor and prevent the cancer from coming back.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.